Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

894 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy.
Semb AG, van Wissen S, Ueland T, Smilde T, Waehre T, Tripp MD, Frøland SS, Kastelein JJ, Gullestad L, Pedersen TR, Aukrust P, Stalenhoef AF. Semb AG, et al. Among authors: kastelein jj. J Am Coll Cardiol. 2003 Jan 15;41(2):275-9. doi: 10.1016/s0735-1097(02)02718-3. J Am Coll Cardiol. 2003. PMID: 12535822 Free article. Clinical Trial.
The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy.
de Grooth GJ, Zerba KE, Huang SP, Tsuchihashi Z, Kirchgessner T, Belder R, Vishnupad P, Hu B, Klerkx AH, Zwinderman AH, Jukema JW, Sacks FM, Kastelein JJ, Kuivenhoven JA. de Grooth GJ, et al. Among authors: kastelein jj. J Am Coll Cardiol. 2004 Mar 3;43(5):854-7. doi: 10.1016/j.jacc.2003.08.056. J Am Coll Cardiol. 2004. PMID: 14998629 Free article.
Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study.
Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Palmer G; Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group. Pedersen TR, et al. Among authors: kastelein jj. Am J Cardiol. 2004 Sep 15;94(6):720-4. doi: 10.1016/j.amjcard.2004.06.003. Am J Cardiol. 2004. PMID: 15374773 Clinical Trial.
Safety of rosuvastatin.
Shepherd J, Hunninghake DB, Stein EA, Kastelein JJ, Harris S, Pears J, Hutchinson HG. Shepherd J, et al. Among authors: kastelein jj. Am J Cardiol. 2004 Oct 1;94(7):882-8. doi: 10.1016/j.amjcard.2004.06.049. Am J Cardiol. 2004. PMID: 15464670 Clinical Trial.
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators. LaRosa JC, et al. Among authors: kastelein jj. N Engl J Med. 2005 Apr 7;352(14):1425-35. doi: 10.1056/NEJMoa050461. Epub 2005 Mar 8. N Engl J Med. 2005. PMID: 15755765 Free article. Clinical Trial.
Lipoprotein lipase gene polymorphisms and the risk of target vessel revascularization after percutaneous coronary intervention.
Monraats PS, Rana JS, Nierman MC, Pires NM, Zwinderman AH, Kastelein JJ, Kuivenhoven JA, de Maat MP, Rittersma SZ, Schepers A, Doevendans PA, de Winter RJ, Tio RA, Frants RR, Quax PH, van der Laarse A, van der Wall EE, Jukema JW. Monraats PS, et al. Among authors: kastelein jj. J Am Coll Cardiol. 2005 Sep 20;46(6):1093-100. doi: 10.1016/j.jacc.2005.05.071. J Am Coll Cardiol. 2005. PMID: 16168296 Free article.
894 results